Immunic Therapeutics IMUX Investor Presentation November 2021

Immunic Therapeutics is developing a pipeline of next-generation selective oral therapies for chronic inflammatory and autoimmune diseases. The presentation outlines the company's lead product candidates including IMU-838, IMU-935, and IMU-856, with details on clinical trial timelines and commercial strategy.